Fasiglifam (TAK-875): Mechanistic Investigation and Retrospective Identification of Hazards for Drug Induced Liver Injury

Otieno, MA; Snoeys, J; Lam, W; Ghosh, A; Player, MR; Pocai, A; Salter, R; Simic, D; Skaggs, H; Singh, B; Lim, HK

Otieno, MA (reprint author), Janssen Pharmaceut, Preclin Dev & Safety, Spring House, PA 19477 USA.

TOXICOLOGICAL SCIENCES, 2018; 163 (2): 374

Abstract

TAK-875, a GPR40 agonist, was withdrawn from Phase III clinical trials due to drug-induced liver injury (DILI). Mechanistic studies were conducted to ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索